Blog Listing

Scynexis: Is The Delay A Buying Opportunity?

SCYX posted earnings and explained the FDA wants more data for its IV formulation.

This delays an important Phase II trial.

We discuss the implications and our fair value estimate.

Read the full article here.

Tags:
SCYX


Leave a Reply